OncoMatch/Gastric / Stomach Cancer/FGFR2
Gastric / Stomach CancerFGFR2 Clinical Trials
2 recruiting trials·Updated daily from ClinicalTrials.gov
FGFR2 amplification or fusion occurs in approximately 5–10% of gastric cancers and defines a targetable subgroup. Bemarituzumab, an FGFR2b-directed antibody, demonstrated survival benefit over chemotherapy in FGFR2b-overexpressing gastric cancer (FIGHT trial). Trials evaluate selective FGFR inhibitors (pemigatinib, futibatinib), FGFR2-directed ADCs, and combination strategies for FGFR2-amplified or overexpressing gastroesophageal adenocarcinoma.
Top recruiting
Top recruiting FGFR2 Gastric / Stomach Cancer trials
Ranked by phase and US site count. See all 2 trials matched to your profile →
Other Gastric / Stomach Cancer biomarkers
Browse other molecular targets with active Gastric / Stomach Cancer trials.